Management of Gout and Hyperuricemia in CKD
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Hyperuricemia and gout, the clinical manifestation of monosodium urate crystal deposition, are common in patients with chronic kidney disease (CKD). While the presence of CKD poses additional challenges in gout management, effective urate-lowering is possible for most patients with CKD. Initial doses of urate-lowering therapy are lower than in the non-CKD population, while incremental dose escalation is guided by regular monitoring of serum urate to reach the target of less than 6 mg/dL (or less than 5 mg/dL for patients with tophi). Management of gout flares with presently available agents can be more challenging due to potential nephrotoxicity and/or contraindications in the setting of other common comorbidities. At present, asymptomatic hyperuricemia is not an indication for urate-lowering therapy, though emerging data may support a potential renoprotective effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout
Becker, M. A., Schumacher, H. R., Wortmann, R. L., MacDonald, P. A., Eustace, D., Palo, W. A., Streit, J., & Joseph-Ridge, N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050373 · Cited by 1,357
Schumacher, H. R., Becker, M. A., Wortmann, R. L., MacDonald, P. A., Hunt, B., Streit, J., Lademacher, C., & Joseph‐Ridge, N. (2008) · Arthritis Care & Research · doi:10.1002/art.24209 · Cited by 638 · cited 2×
“Trials assessing febuxostat’s efficacy compared it to a fixed dose of allopurinol of 300 mg/d, or 200 mg/d in those with some degree of kidney disease.(56-59) Because this allopurinol dose is not sufficient to adequately achieve the serum urate target level for a majority of patients, it is not clear from these trials…”
Yu, M.-A., Sánchez-Lozada, L. G., Johnson, R. J., & Kang, D.-H. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e328337da1d · Cited by 626 · cited 1×
“Hyperuricemia may cause endothelial dysfunction, reflecting the effects of a reduction of nitric oxide bioavailability, the stimulation of oxidative stress, and activation of the renin-angiotensin system.(3,93-95) Oxidative stress can stimulate smooth muscle cell proliferation of the afferent arterioles, thereby decre…”
BECKER, M. A., SCHUMACHER, H. R., MacDONALD, P. A., LLOYD, E., & LADEMACHER, C. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.080814 · Cited by 269 · cited 2×
“In the EXCEL study, 1,086 individuals from 2 prior phase 3 trials(56,57) were enrolled and randomly assigned to either allopurinol, 100 to 300 mg; febuxostat, 80 mg; or febuxostat, 120 mg, and were permitted to switch among these 3 arms during the first 6 months to achieve and maintain the serum urate target.(58)”
Cited by
Hyperuricemia and its related diseases: mechanisms and advances in therapy
Du, L., Zong, Y., Li, H., Wang, Q., Xie, L., Yang, B., Pang, Y., Zhang, C., Zhong, Z., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01916-y · Cited by 631
Düsing, P., Zietzer, A., Goody, P. R., Hosen, M. R., Kurts, C., Nickenig, G., & Jansen, F. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02037-7 · Cited by 224
Metadata
- Authors
- Vargas-Santos, A. B., & Neogi, T.
- Venue
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 70
- Issue
- 3
- Pages
- 422-439
- ISSN
- 0272-6386 (ISSN-L)
- OpenAlex
- W2607903621
- Cited by
- 223
- References
- 5
- FWCI
- 10.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.